StockMacro
Company, fund or insider

Help

Menu

Greenwich LifeSciences

$19.25 -30% in 6 monthsMarket cap $282.6M

GLSI on XNAS, Health Care, Greenwich LifeSciences, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 136% in 12 months but down 30% in six months, while 11% of shares are sold short.

  • BadCash of $5.9M sits against a $24.6M net loss over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Industry
Pharmaceutical preparations (Health Care)
Employees
13
Website
greenwichlifesciences.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $5.8M.
Quarter to 31 Dec 2021: revenue –, net income -$2.4MQuarter to 31 Mar 2022: revenue –, net income -$2.0MQuarter to 30 Jun 2022: revenue –, net income -$746KQuarter to 30 Sep 2022: revenue –, net income -$2.3MQuarter to 31 Dec 2022: revenue –, net income -$2.8MQuarter to 31 Mar 2023: revenue –, net income -$2.1MQuarter to 30 Jun 2023: revenue –, net income -$1.6MQuarter to 30 Sep 2023: revenue –, net income -$2.4MQuarter to 31 Dec 2023: revenue –, net income -$2.7MQuarter to 31 Mar 2024: revenue –, net income -$2.5MQuarter to 30 Jun 2024: revenue –, net income -$2.6MQuarter to 30 Sep 2024: revenue –, net income -$2.7MQuarter to 31 Dec 2024: revenue –, net income -$8.0MQuarter to 31 Mar 2025: revenue –, net income -$3.3MQuarter to 30 Jun 2025: revenue –, net income -$4.0MQuarter to 30 Sep 2025: revenue –, net income -$4.2MQuarter to 31 Dec 2025: revenue –, net income -$9.2MQuarter to 31 Mar 2026: revenue –, net income -$5.7MQuarter to 30 Jun 2026: revenue –, net income -$3.9MQuarter to 30 Sep 2026: revenue –, net income -$5.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $9.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$5.8M
30 Jun 2026–-$3.9M
31 Mar 2026–-$5.7M
31 Dec 2025–-$9.2M
30 Sep 2025–-$4.2M
30 Jun 2025–-$4.0M
31 Mar 2025–-$3.3M
31 Dec 2024–-$8.0M
30 Sep 2024–-$2.7M
30 Jun 2024–-$2.6M
31 Mar 2024–-$2.5M
31 Dec 2023–-$2.7M
30 Sep 2023–-$2.4M
30 Jun 2023–-$1.6M
31 Mar 2023–-$2.1M
31 Dec 2022–-$2.8M
30 Sep 2022–-$2.3M
30 Jun 2022–-$746K
31 Mar 2022–-$2.0M
31 Dec 2021–-$2.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$24.6M -$18.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.73 -$1.37
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $5.9M $3.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$5.9M (net cash) -$3.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Greenwich LifeSciencesGLSI (this company) $282.6Mloss–––
Fulcrum TherapeuticsFULC $281.8Mloss–––
Relmada TherapeuticsRLMD $279.5Mloss–––
Benitec BiopharmaBNTC $285.9Mloss–––
EvommuneEVMN $291.1Mloss–––
Galectin TherapeuticsGALT $271.4Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-8.6%

53 13F filers vs 58

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

12%

1.7M shares held by 13F filers (30 Sep 2026) of 14.7M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

11%

1.6M shares sold short (30 Oct 2026) of 14.7M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

12.5

1.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.7%

1.6M shares sold short in the report before, 1.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

78%

78% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

30

30 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

15×

30 articles in the last 7 days; its usual week has 2.

Price $19.25 on 20 Nov 2026, +136% over 12 months (12-month range $7.85 to $33.56)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $437K in the last 12 months (the 12 months before: $515K).
Institutional holders (13F filers). 53 13F filers reported holding it in the latest 13F quarter, +6.0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
31 Mar 20268-K and other filingsReport will be filed late
24 Jul 20258-K and other filingsChanged its auditor
15 May 20258-K and other filingsReport will be filed late
31 Mar 20258-K and other filingsReport will be filed late
29 Oct 2024Sharp changeShort interest spike: short interest spike, 501K vs usual 181K (2024-10-15); 2.7x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 505K vs usual 181K (2024-09-13); 2.6x the same period a year earlier
18 Jun 20248-K and other filingsPrivate placement of securities (Form D)
15 May 20248-K and other filingsReport will be filed late
1 Apr 20248-K and other filingsReport will be filed late
20 Feb 20248-K and other filingsChanged its auditor
14 Aug 20238-K and other filingsReport will be filed late
15 May 20238-K and other filingsReport will be filed late
16 May 20228-K and other filingsReport will be filed late
5 Jan 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 134K)
Insider net buying (open market)
Month from 1 Dec 2021: $85K published
Month from 1 Jan 2022: $131K published
Month from 1 Feb 2022: $216K published
Month from 1 Apr 2022: $222K published
Month from 1 Jun 2022: $744K published
Month from 1 Oct 2022: $67K published
Month from 1 Nov 2022: $18K published
Month from 1 Dec 2022: $60K published
Month from 1 Jan 2023: $119K published
Month from 1 Feb 2023: $73K published
Month from 1 Mar 2023: $19K published
Month from 1 Apr 2023: $174K published
Month from 1 May 2023: $14K published
Month from 1 Jul 2023: $12K published
Month from 1 Aug 2023: $31K published
Month from 1 Sep 2023: $51K published
Month from 1 Oct 2023: $66K published
Month from 1 Nov 2023: $87K published
Month from 1 Feb 2024: $261K published
Month from 1 Mar 2024: $511K published
Month from 1 Apr 2024: $57K published
Month from 1 Jun 2024: $2.5M published
Month from 1 Jul 2024: $40K published
Month from 1 Aug 2024: $115K published
Month from 1 Sep 2024: $11K published
Month from 1 Oct 2024: $22K published
Month from 1 Nov 2024: $13K published
Month from 1 Jan 2025: $201K published
Month from 1 Apr 2025: $165K published
Month from 1 Nov 2025: $149K published
Month from 1 Dec 2025: $52K published
Month from 1 Jan 2026: $288K published
Month from 1 Jul 2026: $97K published
Institutional holders (13F filers)
31 Dec 2021 report: 33; public on 14 Feb 2022
31 Mar 2022 report: 33; public on 16 May 2022
30 Jun 2022 report: 33; public on 15 Aug 2022
30 Sep 2022 report: 20; public on 14 Nov 2022
31 Dec 2022 report: 22; public on 14 Feb 2023
31 Mar 2023 report: 26; public on 15 May 2023
30 Jun 2023 report: 22; public on 14 Aug 2023
30 Sep 2023 report: 22; public on 14 Nov 2023
31 Dec 2023 report: 24; public on 14 Feb 2024
31 Mar 2024 report: 30; public on 15 May 2024
30 Jun 2024 report: 32; public on 14 Aug 2024
30 Sep 2024 report: 39; public on 14 Nov 2024
31 Dec 2024 report: 41; public on 14 Feb 2025
31 Mar 2025 report: 45; public on 15 May 2025
30 Jun 2025 report: 47; public on 14 Aug 2025
30 Sep 2025 report: 50; public on 14 Nov 2025
31 Dec 2025 report: 48; public on 17 Feb 2026
31 Mar 2026 report: 62; public on 15 May 2026
30 Jun 2026 report: 58; public on 14 Aug 2026
30 Sep 2026 report: 53; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short sale volume on FINRA-reported off-exchange venues (TRFs + ADF), shares per day at 148K (20 Nov 2026), 4.0× its normal reading; higher than 97% of its own history.
  • Insider net buying (open market): Insiders bought a net $437K in the last 12 months (the 12 months before: $515K).
  • Institutional holders (13F filers): 53 13F filers reported holding it in the latest 13F quarter, +6.0% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 30 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
30 Jul 2026Snehal PatelCEO and CFOBuy2,200$13.43$30KForm 4
29 Jul 2026Snehal PatelCEO and CFOBuy1,500$13.62$20KForm 4
27 Jul 2026Snehal PatelCEO and CFOBuy3,600$13.06$47KForm 4
15 Jan 2026Snehal PatelCEO and CFOBuy1,800$29.83$54KForm 4
14 Jan 2026Snehal PatelCEO and CFOBuy2,900$27.54$80KForm 4
5 Jan 2026Snehal PatelCEO and CFOBuy4,300$21.36$92KForm 4
2 Jan 2026Snehal PatelCEO and CFOBuy2,900$21.73$63KForm 4
19 Dec 2025Snehal PatelCEO and CFOBuy4,100$12.62$52KForm 4

53 institutions reported shares at the end of Q3 2026, 12% of the shares outstanding; 3 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.512K3.49%$9.2M+26K+5.4%
Vanguard Capital Management LLC289K1.97%$5.2M+10K+3.7%
Geode Capital Management, LLC187K1.28%$3.4M+19K+11%
State Street Corp159K1.09%$2.9M+16K+11%
Vanguard Portfolio Management LLC93K0.63%$1.7M+12K+15%
Northern Trust Corp83K0.56%$1.5M+2,526+3.1%
Goldman Sachs Group Inc57K0.39%$1.0M+17K+44%
Vanguard Fiduciary Trust Co53K0.36%$961K+7,261+16%
Bank of New York Mellon Corp49K0.33%$884K+1,099+2.3%
STRS Ohio35K0.24%$626K+17K+95%

Company events

All 23 company events

In 12 months: 1 late report. Results releases and routine reports are left out.

FiledWhat happenedSource
31 Mar 2026Annual report will be filed lateNT 10-K
24 Jul 2025Changed its auditor8-K
15 May 2025Quarterly report will be filed lateNT 10-Q
31 Mar 2025Annual report will be filed lateNT 10-K
17 Jun 2024Signed a major agreementSame filing: sold shares privately8-K
17 Jun 2024Private placement of securities (Form D)$2.5M sold of $2.5M offeredD
15 May 2024Quarterly report will be filed lateNT 10-Q
1 Apr 2024Annual report will be filed lateNT 10-K

The 5 newest of 135 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 31 Jul 2026Insiders record

    Patel Snehal (CEO and CFO) bought 2,200 shares of GLSI ($29,555) (dated 30 Jul 2026)

  2. 30 Jul 2026Insiders record

    Patel Snehal (CEO and CFO) bought 1,500 shares of GLSI ($20,430) (dated 29 Jul 2026)

  3. 28 Jul 2026Insiders record

    Patel Snehal (CEO and CFO) bought 3,600 shares of GLSI ($47,018) (dated 27 Jul 2026)

  4. 31 Mar 2026Filings record

    Report will be filed late

  5. 16 Jan 2026Insiders record

    Patel Snehal (CEO and CFO) bought 1,800 shares of GLSI ($53,694) (dated 15 Jan 2026)

  6. 15 Jan 2026Insiders record

    Patel Snehal (CEO and CFO) bought 2,900 shares of GLSI ($79,866) (dated 14 Jan 2026)

  7. 6 Jan 2026Insiders record

    Patel Snehal (CEO and CFO) bought 4,300 shares of GLSI ($91,848) (dated 5 Jan 2026)

  8. 3 Jan 2026Insiders record

    Patel Snehal (CEO and CFO) bought 2,900 shares of GLSI ($63,017) (dated 2 Jan 2026)

  9. 20 Dec 2025Insiders record

    Patel Snehal (CEO and CFO) bought 4,100 shares of GLSI ($51,742) (dated 19 Dec 2025)

  10. 29 Nov 2025Insiders record

    Patel Snehal (CEO and CFO) bought 4,600 shares of GLSI ($38,502) (dated 28 Nov 2025)

  11. 13 Nov 2025Insiders record

    Patel Snehal (CEO and CFO) bought 10,600 shares of GLSI ($89,358) (dated 12 Nov 2025)

  12. 5 Nov 2025Insiders record

    Patel Snehal (CEO and CFO) bought 2,300 shares of GLSI ($21,298) (dated 4 Nov 2025)

  13. 24 Jul 2025Filings record

    Changed its auditor

  14. 15 May 2025Filings record

    Report will be filed late

  15. 30 Apr 2025Insiders record

    Patel Snehal (CEO and CFO) bought 3,600 shares of GLSI ($35,568) (dated 29 Apr 2025)

  16. 23 Apr 2025Insiders record

    Patel Snehal (CEO and CFO) bought 5,400 shares of GLSI ($48,492) (dated 22 Apr 2025)

  17. 9 Apr 2025Insiders record

    Patel Snehal (CEO and CFO) bought 3,600 shares of GLSI ($32,760) (dated 8 Apr 2025)

  18. 8 Apr 2025Insiders record

    Patel Snehal (CEO and CFO) bought 5,500 shares of GLSI ($48,015) (dated 7 Apr 2025)

  19. 31 Mar 2025Filings record

    Report will be filed late

  20. 14 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 2,500 shares of GLSI ($31,275) (dated 13 Jan 2025)

  21. 9 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 2,900 shares of GLSI ($39,391) (dated 8 Jan 2025)

  22. 8 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 3,400 shares of GLSI ($44,030) (dated 7 Jan 2025)

  23. 7 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 2,000 shares of GLSI ($23,940) (dated 6 Jan 2025)

  24. 4 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 2,400 shares of GLSI ($27,264) (dated 3 Jan 2025)

  25. 3 Jan 2025Insiders record

    Patel Snehal (CEO and CFO) bought 3,200 shares of GLSI ($35,584) (dated 2 Jan 2025)

  26. 26 Nov 2024Insiders record

    Thompson Jaye (VP Clinical Reg Affairs) bought 1,000 shares of GLSI ($12,910) (dated 25 Nov 2024)

  27. 25 Oct 2024Short interest and volume change

    had 501K shares sold short in the 15 Oct 2024 report, 2.7× the same report last year.

    Same report last year: 184K; its normal report is 181K.

    See the evidence
    This period
    501K (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    181K
    Typical spread (median absolute deviation)
    34K
    How far from its usual level
    +6.3
    Same report last year
    184K
    History used
    1,476 days
    2023-10-13: 184K2023-10-31: 164K2023-11-15: 167K2023-11-30: 167K2023-12-15: 115K2023-12-29: 152K2024-01-12: 161K2024-01-31: 155K2024-02-15: 174K2024-02-29: 121K2024-03-15: 137K2024-03-28: 140K2024-04-15: 185K2024-04-30: 189K2024-05-15: 177K2024-05-31: 195K2024-06-14: 229K2024-06-28: 260K2024-07-15: 371K2024-07-31: 416K2024-08-15: 452K2024-08-30: 467K2024-09-13: 505K2024-09-30: 496K2024-10-15: 501K
    the 15 Oct 2024 report24 earlier reportsnormal: 181K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 1 Oct 2024Insiders record

    Patel Snehal (CEO and CFO) bought 1,500 shares of GLSI ($21,945) (dated 30 Sep 2024)

  29. 25 Sep 2024Short interest and volume change

    had 505K shares sold short in the 13 Sep 2024 report, 2.6× the same report last year.

    Same report last year: 195K; its normal report is 181K.

    See the evidence
    This period
    505K (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    181K
    Typical spread (median absolute deviation)
    23K
    How far from its usual level
    +6.5
    Same report last year
    195K
    History used
    1,444 days
    2023-09-15: 195K2023-09-29: 195K2023-10-13: 184K2023-10-31: 164K2023-11-15: 167K2023-11-30: 167K2023-12-15: 115K2023-12-29: 152K2024-01-12: 161K2024-01-31: 155K2024-02-15: 174K2024-02-29: 121K2024-03-15: 137K2024-03-28: 140K2024-04-15: 185K2024-04-30: 189K2024-05-15: 177K2024-05-31: 195K2024-06-14: 229K2024-06-28: 260K2024-07-15: 371K2024-07-31: 416K2024-08-15: 452K2024-08-30: 467K2024-09-13: 505K
    the 13 Sep 2024 report24 earlier reportsnormal: 181K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 17 Sep 2024Insiders record

    Thompson Jaye (VP Clinical Reg Affairs) bought 800 shares of GLSI ($11,080) (dated 16 Sep 2024)

  31. 9 Aug 2024Insiders record

    Patel Snehal (CEO and CFO) bought 2,000 shares of GLSI ($27,620) (dated 8 Aug 2024)

  32. 8 Aug 2024Insiders record

    Patel Snehal (CEO and CFO) bought 5,500 shares of GLSI ($72,490) (dated 7 Aug 2024)

  33. 6 Aug 2024Insiders record

    Thompson Jaye (VP Clinical Reg Affairs) bought 1,000 shares of GLSI ($15,150) (dated 5 Aug 2024)

  34. 25 Jul 2024Insiders record

    Patel Snehal (CEO and CFO) bought 1,500 shares of GLSI ($23,835) (dated 24 Jul 2024)

  35. 23 Jul 2024Insiders record

    Thompson Jaye (VP Clinical Reg Affairs) bought 1,000 shares of GLSI ($16,000) (dated 22 Jul 2024)

  36. 18 Jun 2024Insiders record

    Patel Snehal (CEO and CFO) bought 174,825 shares of GLSI ($2.5M) (dated 17 Jun 2024)

  37. 18 Jun 2024Filings record

    Private placement of securities (Form D) (dated 17 Jun 2024)

  38. 15 May 2024Filings record

    Report will be filed late

  39. 4 Apr 2024Insiders record

    Patel Snehal (CEO and CFO) bought 3,000 shares of GLSI ($57,240) (dated 3 Apr 2024)

  40. 1 Apr 2024Filings record

    Report will be filed late

Showing the newest 40 of 125 entries; narrow the window or the kind of data to see older ones.

Not listed: 50 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001799788
Ticker
GLSI
Domain
greenwichlifesciences.com
Hq location
TX|STAFFORD|77477 (1 unverified)
Name
Greenwich LifeSciences, Inc.
  • SEC Form 13F institutional holdings225 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)69 records1 Jun 2020 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)324 data points31 Dec 2018 to 6 Nov 2026
  • SEC Form 4 insider transactions118 records, 416 data points29 Sep 2020 to 30 Jul 2026
  • FINRA short interest (twice monthly)437 data points30 Sep 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3094 data points25 Sep 2020 to 20 Nov 2026